Factors Associated with Glycemic Control and Diabetes-Related Costs in Patients with Diabetes in the United Arab Emirates: Results From A Retrospective Large Claims Data Analysis

Introduction: Hyperuricemia is common Type 2 diabetes at very high cardiovascular risk. Objective: Evaluate the relationship between hyperuricemia and diabetes type 2, and determine its predictive factors in this population. Patients and Methods: Retrospective study cross including 190 patients with diabetes type 2 hospitalized Service of Endocrinology of CHU Ibn Rushd Casablanca from January 2015 to December 2017. Hyperuricemia was defined as a serum uric acid concentration> 70 mg/L (men) and> 60 mg/L (women). The variables studied were the anthropometric measurements), cardiovascular factors (tobacco, hypertension, dyslipidemia), and degenerative complications (retinopathy, neuropathy, kidney failure, ischemic heart disease). The analyzes were performed by SPSS software. Results: Hyperuricemia was found in 26.5% of patients with a female predominance (76%), an average age of 55.9 years, and an average age of 12.4ans diabetes. The glycemic control was found in 84.6% of cases with mean glycated hemoglobin 8.6%. Factors associated al hyperuricemia were the blood pressure in 86% (p <0.05), dyslipidemia in 76.3% of cases (p <0.001) with hypertriglyceridemia in 48.3% of cases (p <0.02), and a hypoHDLémie 28% (p <0.001). The age, obesity, smoking, and glycemic control were associated significantly n al hyperuricemia. The research of degenerative complications of hyperuricemia has objectified renal impairment (GFR between 15 and 60ml / min) chez47% (p <0.001), it was kind of moderate in 35.8% (p <0.01) and severe in 5.1% (p <0.02), ischemic heart disease was found in 34% of cases (p <0.01). Conclusion: In our study, hyperuricemia in type 2 diabetes is common in female patients, especially with hypertension, dyslipidemia, and renal failure. Other factors such as age, obesity, smoking is not associated with hyperuricemia in type 2 diabetics.

Download Full-text

MYOCARDIAL INFARCTION CARE IN SOCIOECONOMIC ENVIRONMENTS - CLAIMS DATA ANALYSIS

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(21)02995-8 ◽

2021 ◽

Vol 77 (18) ◽

pp. 1639

Author(s):

Alexander Hilt ◽

Victor Umans ◽

Tessel N.E. Vossenberg ◽

Martin Schalij ◽

Saskia Beeres

Keyword(s):

Myocardial Infarction ◽

Data Analysis ◽

Claims Data ◽

Claims Data Analysis

Download Full-text

PDB35 Trajectory of Glycated Hemoglobin Over Time Among Obese Type 2 Diabetes Patients Prescribed U-100 Basal-only Insulin Regimens: A US Administrative Claims Data Analysis

Value in Health ◽

10.1016/j.jval.2021.04.432 ◽

2021 ◽

Vol 24 ◽

pp. S84

Author(s):

K. Maughn ◽

J. Chen ◽

D.R. Nelson ◽

L. Fan ◽

Y. Liu ◽

...

Keyword(s):

Type 2 Diabetes ◽

Data Analysis ◽

Claims Data ◽

Glycated Hemoglobin ◽

Administrative Claims ◽

Administrative Claims Data ◽

Claims Data Analysis ◽

Over Time ◽

Diabetes Patients

Download Full-text

Abstract 275: Concomitant Statin Use With Ezetimibe Or Colesevelam For Treatment Of Hypercholesterolemia

Circulation Cardiovascular Quality and Outcomes ◽

10.1161/circoutcomes.6.suppl_1.a275 ◽

2013 ◽

Vol 6 (suppl_1) ◽

Author(s):

Xin Ye ◽

Harold Bays ◽

Philip Schwab

Keyword(s):

Index Date ◽

Claims Data ◽

Study Objective ◽

Factors Associated ◽

Patient Demographics ◽

Pharmacy Claims ◽

Before And After ◽

Charlson Comorbidity Score ◽

Claims Data Analysis ◽

Statin Use

OBJECTIVES: Ezetimibe or colesevelam are often used for treating hypercholesterolemia when statin therapy is insufficient or not well tolerated. Our study objective was to examine prevalence of concomitant statin use and associated factors among hypercholesterolemia patients newly treated with ezetimibe or colesevelam. METHODS: This analysis evaluated a large health plan’s Commercial and Medicare Advantage claims data from 1/1/08 to 7/31/12. The first ezetimibe (excluding fixed combination therapy of ezetimibe/simvastatin) or colesevelam prescription fill date during this period was identified as the index date. Patients were assigned to either ezetimibe or colesevelam cohort based on the index drug and were required to have ≥ 2 consecutive prescriptions for the index drug and have at least 6 months and 12 months continuous enrollment before and after the index date, respectively. Prevalence of concomitant statin use was identified based on pharmacy claims. Patient demographics and clinical characterisitics were explored to examine the factors associated with concomitant statin use using multivariate logistic regression. RESULTS: A total of 679 colesevelam and 1439 ezetimibe patients were included in this study. The concomitant use of statins was 24% among colesevelam and 50% among ezetimibe patients, respectively. After adjustment for patient demographics and comorbidities, ezetimibe patients were 3.2 times more likely than colesevelam patients to have concomitant statin use (OR= 3.168, 95% CI: 2.573, 3.900, P<0.001). Other significant factors associated with higher concomitant statin use include: male gender (OR= 1.296, 95%: 1.079, 1.558, P=0.006), presence of diabetes mellitus (OR=1.262, 95% CI: 1.035, 1.539, P=0.021) and higher Charlson comorbidity score (OR=1.114, 95% CI: 1.046, 1.187, P<0.001) CONCLUSIONS: In this claims data analysis, statins were administered along with ezetimibe more frequently than administered with colesevelam, which should be taken into account when evaluating effectiveness of ezetimibe vs. colesevelam in the real-world treatment of hypercholesterolemia.

Download Full-text

P230 DEMOGRAPHICS, TREATMENT PATTERNS, AND MORBIDITY IN PATIENTS WITH EXERCISE-INDUCED BRONCHOCONSTRICTION: AN ADMINISTRATIVE CLAIMS DATA ANALYSIS

Annals of Allergy Asthma & Immunology ◽

10.1016/j.anai.2019.08.296 ◽

2019 ◽

Vol 123 (5) ◽

pp. S42-S43

Author(s):

M. Lanz ◽

I. Gilbert ◽

N. Goshi ◽

H. Gandhi ◽

L. Moore-Schiltz ◽

...

Keyword(s):

Data Analysis ◽

Claims Data ◽

Treatment Patterns ◽

Administrative Claims ◽

Administrative Claims Data ◽

Exercise Induced ◽

Claims Data Analysis

Download Full-text

Investigating the effects of operators on warranty cost under sales delay conditions

Journal of Quality in Maintenance Engineering ◽

10.1108/jqme-03-2017-0023 ◽

2018 ◽

Vol 24 (2) ◽

pp. 244-259

Author(s):

Sepideh Eskandari Dorabati ◽

Ali Zeinal Hamadani ◽

Hamed Fazlollahtabar

Keyword(s):

Data Analysis ◽

Design Methodology ◽

Claims Data ◽

Time Interval ◽

Content Type ◽

Proposed Model ◽

Warranty Cost ◽

Warranty Costs ◽

Warranty Claims ◽

Claims Data Analysis

Purpose Due to the fact that the non-standard products, being used by customers, may cause failures in products with sales delays, which naturally affect the warranty policy. Thus, it seems to be necessary to study these two concepts simultaneously. The paper aims to discuss these issues. Design/methodology/approach In this paper, a model is developed for estimating the expected warranty costs under sales delay conditions when two operator costs (failing but not reported and non-failing but reported) are included. Findings The proposed model is validated using a numerical example for a two types of intermittent and fatal failures occur under a non-renewing warranty policy. Originality/value Sales delay is the time interval between the date of production and the date of sale. Most reported literature on warranty claims data analysis related to sales delay have mainly focussed on estimating the probability distribution of the sales delay.

Download Full-text